PHAM QUANG X (CEO and Chairman) sold 9.5% of their position (11.16K shares) of CADRENAL THERAPEUTICS, INC. on the open market
Open‑market sale worth $33.9K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 2 sales
Filed: 6/27/2026ACC: 0001213900-26-072789
DirectorOfficer10% Owner· CEO and Chairman
Since Jan 2023
-11.16K
Net shares
Net seller
$33.9K
Total sold
2
Open market trades
0B · 2S
2
Total transactions
11.16K disposed
Non-Derivative Transactions2
Common Stock
Direct
Shares
−2.13K
Price / share
$3.00
Trade value
$6.38K
% of position
1.8%
6/25/2026
117.14K→115.02K
Common Stock
Direct
Shares
−9.03K
Price / share
$3.05
Trade value
$27.54K
% of position
7.9%
6/26/2026
115.02K→105.99K
Total
Net shares
−11.16K
Net value
-$33.92K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 6/25/2026 | S · Sale | −2.13K | $3.00 | $6.38K | 1.8% | 117.14K | 115.02K |
| Common Stock Direct | 6/26/2026 | S · Sale | −9.03K | $3.05 | $27.54K | 7.9% | 115.02K | 105.99K |
| Total | −11.16K | -$33.92K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)1
Common Stock
IndirectShares owned200K
Total
200K indirect200K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock | 200K | Indirect |
| Total | 200K | 200K indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported